

Observations on the Global Activism Environment in Q1 2025

	 Despite largely unexpected economic uncertainty, global campaign activity remained strong with 70 campaigns YTD, up 17% year-over-year
	 Increasing market volatility did not dampen activist activity, with consistent levels of activity in each month of Q1
Surging U.S. Activity Leads Another Strong Q1	 U.S. activity is up 43% year-over-year with 40 campaigns, following two years in which the U.S. comprised less than half of global activity
Leads Another Grong &	 Japan was the second-most active jurisdiction with 16 campaigns, a 45% increase year-over-year, as the country continues to attract international and local activist attention
	 European campaign activity continues to be subdued, with 10 campaigns YTD (five in the U.K.) notably (~33%) below the four- year average of 15
2	Only 26% of campaigns YTD have featured an M&A thesis vs. the 45% four-year average
Bursh Ha Commissions	Break-up campaigns have been the most popular M&A thesis, appearing in 10% of campaigns
Break-Up Campaigns Popular Despite Fewer M&A Demands Overall	 Prominent companies, including Becton Dickinson, Honeywell and Solventum, announced break-ups in Q1 following pressure from activists
	 With continued M&A uncertainty, activists remain focused on strategic and operational changes at targets (24% of campaigns YTD, 23% above the four-year average), consistent with 2024
3	51 Board seats have been won YTD, 34% above 2024's YTD total
Authorita Mana Caranactal	 29 campaigns have settled YTD vs. 22 in 2024 YTD
Activists More Successful Gaining Board Seats in	There are currently 13 finished or prospective proxy fights in the U.S. vs. 10 in 2024 YTD
2025	 2025 has seen two notable proxy fight outcomes: Air Products / Mantle Ridge (shareholders did not re-elect the incumbent CEO) and Matthews / Barington (victory for the Company despite both proxy advisors recommending for all dissident nominees)
Changes at ISS and in the Regulatory Regime Inject	 February 2025 SEC guidance regarding specific actions that may force an institutional investor to file an active 13D instead of passive 13G has led many investors to reassess their corporate engagement approaches
Uncertainty Into Proxy Season	 For the first time since 2017, ISS has a new Head of Special Situations Research following Cristiano Guerra's departure, with ISS veteran Andrew Borek assuming the role

Source: Bloomberg, FactSet, Diligent Market Intelligence, 13D Monitor, press reports and publicly available data and sources. Market data as of 3/31/2025.


Note: All data is for campaigns conducted globally by activists at companies with market capitalizations greater than \$500 million due to depressed valuation at the time of campaign announcement (company was larger than \$500mm in prior twelve months).



Activity Remains Elevated to Start 2025

Despite unexpected economic uncertainty and equity market volatility, campaign activity has exceeded 2024's pace








Surging U.S. Activity Drives Global Campaigns


The U.S. comprised 57% of activity in Q1, following two years in which it comprised less than 50% of global activity





Activist Activity by Sector

Q1 2025 witnessed significant concentration in the Industrials, Technology and Healthcare sectors, trending significantly above four-year activity averages






Activist Activity by Quarter


Accelerated Q1 2025 activity, 25% above the four-year quarterly average

Quarterly Campaign Activity





Activist Targets by Company Size





As of initial campaign announcement.

^{2.} Stake not disclosed.

Notable Q1 Campaign Developments & Launches

Notable Launches

Notable Updates

							•
Launch Date	Activist(s)	Company / Market Cap ⁽¹⁾	Highlights	Launch Date	Activist(s)	Company / Market Cap ⁽¹⁾	Notable Updates
2/25	ELLIOTT	bp \$92.3bn	In February, Elliott reportedly built a stake in BP and urged the Company to pursue transformative measures to improve its performance At its Investor Day, BP announced it would refocus on its oil and gas business and launched a strategic review for its Castrol lubricants business In March, Elliott reportedly urged the	11/24	ELLIOTT	Honeywell \$152.1bn	In February, Honeywell announced plan to separate its Automation and Aerospace divisions, following pressure from Elliott for the conglomerate to break up
		φ92.30Π	Company to sell its renewable power projects			\$152.1bH	
			In February, Starboard reportedly built a stake				In January, Ananym was reportedly preparing to nominate up to six Directors for election at Henry Schein's upcoming AGM
2/25	STARBOARD VALUE	⇔ BD	in Becton Dickinson and urged the Company to divest its Life Sciences business Becton Dickinson subsequently announced the Board authorized a plan to separate its Life Sciences business		KKR	✓ HENRY SCHEIN®	Later in January, Henry Schein announced a strategic investment by KKR of \$250mm, making it a 12% shareholder, and appointed two KKR principals to its Board; the Company also authorized an increase of \$500mm to its share repurchase program and added a third.
		71.1bn				9.2bn	independent Director
1/25 /	\ NCORA	®.3bn	In January, Ancora nominated nine Directors to U. S. Steel's Board, seeking to replace the Company's CEO and engage in a new standalone strategy instead of pursuing its transaction with Nippon Steel	7/24	TRIAN PARTNERS	S solventum	 In January, Trian urged Solventum to simplify its portfolio and outline a long-range plan that would restore performance to pre-spin levels In February, Solventum announced the sale of its Purification & Filtration business to Thermo Fisher in a ~\$4.1bn all-cash deal
1/25	GARDEN INVESTMENTS	THE MIDDLEBY CORPORA	In January, Garden Investments reportedly urged Middleby to refocus on its core commercial food business, and planned to seek Board seats Middleby stated its was weighing a broad range of strategic alternatives days after Garden's investment	11/23	ELLIOTT	PHILLIPS 66	 In February, Elliott disclosed a \$2.5bn stake in Phillips 66, and urged the Company to sell or spin off its Midstream business and enhance oversight with new independent Directors Elliott later nominated four Directors and submitted a shareholder proposal to

Source: Bloomberg, FactSet, Diligent Market Intelligence, 13D Monitor, press reports and publicly available data and sources.

one Board seat

In February, Middleby settled with Garden for

1. Market cap as of campaign announcement date, or as of initial date of disclosure. In the case of multiple activists, represents market cap as of earliest campaign announcement date or initial disclosure.



declassify the Board

51.9bn

9.1bn

Top Activists of Q1 2025


The most active activist of Q1 was APAC-focused as activity in the region continues to increase

Rank	Activist	Q1 2025 Campaigns Launched	Q1 2025 Target Companies	2024 Rank
1	Murakami Funds	5	FOR TOPO FURUKAWA KELECTRIC GROUP 京意電鉄	8
T2	ELLIOTT	4	easpentech Somiths Sumitomo Reality & Development	1
T2	Δ Engine	4	LKQ lyft vision smiths	T10
4	OASIS	3	TAIYO HOLDINGS	4
T5	(Vision One)	2	Chemours ingevity.	T37
T5	LANDandBUILDINGS	2	Aimco REALTY GROUP	9
T5	NAV	2	MITSUBISHI PENCIL NORITZ	T37
T5	FARALLON ESTABLISHED 1980	2	aste] (NIKKON Holdings Co., Ltd.	T37
T5	STARBOARDVALUE	2	BD QOCVO	3
T5	∧NCORA™	2 ⁽¹⁾	LKQ USS	T21
	Top 10 Total	28	40% of all Q1 2025 campaigns	



Global Activist Universe

53 unique activists, including 11 first-timers, launched campaigns in Q1 2025



Source: Bloomberg, FactSet, Diligent Market Intelligence, 13D Monitor, press reports and publicly available data and sources. Market data as of 3/31/2025.

Note: All data is for campaigns conducted globally by activists at companies with market capitalizations greater than \$500 million at time of campaign announcement; select campaigns with market capitalizations less than \$500 million due to depressed valuation at the time of campaign announcement (company was larger than \$500mm in prior twelve months).


^{. &}quot;Other" includes hedge funds, private equity funds, venture capital, individuals, family offices, long-only institutions, corporates and other miscellaneous activists that have launched at least one previous campaign.

Major activist hedge funds include: Cevian, Elliott Management, Icahn Associates, JANA Partners, Land & Buildings, Sachem Head, Starboard Value, TCI, Third Point, Trian Partners and ValueAct.



U.S. Campaign Activity

40 U.S. campaigns, up 43% year-over-year, have comprised over half of global activity YTD






Europe Campaign Activity



European activity remains muted with only 10 campaigns, trending (~33%) below the four-year average of 15



Source: Bloomberg, FactSet, Diligent Market Intelligence, 13D Monitor, press reports and publicly available data and sources. Market data as of 3/31/2025.

Note: All data is for campaigns conducted globally by activists at companies with market capitalizations greater than \$500 million due to depressed valuation at the time of campaign announcement; select campaign announcement; select campaign announcement; select campaign announcement; select campaign announcement (company was larger than \$500mm in prior twelve months).



European Activity by Country




The U.K. continues to drive the majority of European activity, albeit down (38%) year-over-year





APAC Campaign Activity
APAC activity continues to be burgeoned by Japan, which comprises nearly all regional activity






Key Campaign Objectives in Q1 2025

Activists have not yet refocused on M&A amid market uncertainty, instead continuing to focus on Board change and corporate strategy

Q1 2025 Global Breakdown of Key Objectives



Source: Bloomberg, FactSet, Diligent Market Intelligence, 13D Monitor, press reports and publicly available data and sources. Market data as of 3/31/2025.

Note: All data is for campaigns conducted globally by activists at companies with market capitalizations greater than \$500 million at time of campaign announcement; select campaigns with market capitalizations less than \$500 million due to depressed valuation at the time of campaign announcement (company was larger than \$500mm in prior twelve months). Campaign objectives based on percent of campaigns in which a demand was made. As a result, percentages do not sum to 100%.



Market Cap

(Stake) (\$bn)(1)

\$44.8bn

 $(--)^{(2)}$

5.0bn

(0.6%)

1.8bn

(0.9%)

71.1bn

 $(--)^{(2)}$

9.1bn

(5.0%)

7.8bn

(4.3%, 2.0%)

152.1bn

(3.3%)

9.3bn


 $(--)^{(2)}$

51.9bn

(1.9%)

Global M&A Campaign Activity

Agitating targets for break ups or divestitures was the most popular M&A demand in Q1 2025



🜟 - Company announced break up / divestiture or strategic review




As of initial campaign announcement.

Stake not disclosed.

Global Board Seats Won

51 Board seats won in Q1 2025, up 34% year-over-year





U.S. Dissident Proxy Fights in 2025


Activists continue to launch proxy fights to effectuate change with 13 fights YTD vs. 10 in 2024

AGM Date	Company	/ / Activist	Seats Sought	Seats Won	ISS Dissident Rec. / Won	Glass Lewis Dissident Rec. / Won	
1/23	PRODUCTS (A)	MANTLE R I D G E	4	3	3/3	4/3	Incumbent CEO Seifi Ghaser lost his Board seat
2/20	Matthews INTERNATIONAL*	BARINGTON BARINGTON CAPITAL GROUP, L.P.	3	0	3/0	3/0	
5/6	(U _S S) /	∧NCORA™	9				Highly unusual victory for
5/21	PHILLIPS /	ELLIOTT	4				management subsequent to unanimous proxy advisor support for the activist
5/22*	NATIONAL BEAUTH ENVESTORS	LANDandBUILDINGS	2				
5/23*	DYNAVAX /	DEEP TRACK	4				
6/3*	Portillo's	ENGAGED CAPITAL	2				
6/4*	PENN	HG VORA	3				
6/11*	pacira. /	DOMA PERPETUAL CAPITAL MANAGENEN	3				
6/13*	lyA /	Δ Engine	2				
6/18*	BROOKDALE/	ORTELIUS &	6				
6/19*	© CANNAE HOLDINGS, INC.	CARRONADE CAPITAL	4				
7/16*	✓ AUTODESK	STARBOARD VALUE	3				
Total YTD:	13 Can	npaigns	49	3	6/3	7/3	Data not yet available



Global Board Seat Settlements

Number of settlements up 32% year-over-year





Regulatory and Ecosystem Developments Impacting Activism

Regulatory	SEC 13G Guidance Changes on Shareholder Engagement	 New SEC guidance provides it will consider "influencing" to include attempts to exert "pressure on management to implement specific measures or changes to policy" such as "implicitly or explicitly conditioning" voting support for directors at AGMs with respect to recommendations traditional governance and ESG matters The new guidance also applies to control-related matters, such as a sale of the company or the election of directors not nominated by the company Subsequent to the new guidance, many large institutional investors initially paused and reevaluated their engagement approach Institutional investors will likely reestablish procedures around engagement that allow direct meetings with issuers, but their feedback in these meetings may be limited
Activist Ecosystem	Changing of the Guard at ISS	 In February, ISS Head of Special Situations Research Cristiano Guerra left ISS to join Strategic Governance Advisors Guerra has been replaced by Andrew Borek, a 12-year veteran of ISS ISS retains the same framework for assessing contested elections

Source: Press reports and public filings.



Themes to Watch for the Rest of 2025

- Activists thrive under uncertainty which new targets will present themselves in the event of a sustained market downturn?
- Will break-up demands persist in an uncertain M&A market?
- After a difficult 2024 for activists in contested situations, will 2025's early success continue?
- Will other sponsors follow KKR's toehold / white knight approach at Henry Schein to deploy dry powder?
- Does the balance of power between issuers and activists shift due to incremental regulatory developments and / or personnel changes at proxy advisors?



Barclays Global Shareholder Advisory Group – Key Contacts



Jim Rossman
Global Head of Shareholder
Advisory (New York)
jim.rossman@barclays.com
(212) 526 9531



Christopher Ludwig

Head of Shareholder Advisory
(New York)

christopher.ludwig@barclays.com
(212) 526 2195



James Potts

Head of EMEA Shareholder
Advisory (London)
james.potts @barclays.com
+44 20 7773 4136



Quinn Pitcher
Vice President (New York)
quinn.pitcher@barclays.com
(212) 526 5010



Joshua Jacobs
Associate (New York)
joshua.jacobs@barclays.com
(212) 526 4982




Dominic Pinion

Analyst (New York)

dominic.pinion @barclays.com
(212) 526 9627







Q1 2025 North America Campaigns

Country	Announce Date	Target	Sector	Market Cap	Activist	O/S%	Market Value	Initial Campaign Objective	
Canada	3/10/2025	InterRent REIT	Real Estate	\$1,059	Anson Funds	9.0%	\$95	Strategy / Operations	
Jnited States	3/31/2025	Warner Bros Discovery	Communications & Media	\$26,340	Sessa Capital	1.0%	\$263	Board Change	
Jnited States	3/25/2025	Lyft	Technology	\$5,114	Engine Capital	1.0%	\$51	M&A - Agitate for Sale, Strategy / Operations, Governance	
Jnited States	3/25/2025	Illumina	Healthcare	\$13,865	Corvex Mgmt.	2.5%	\$347	Board Change	
Jnited States	3/24/2025	Kenvue	Consumer	\$44,666	TOMS Capital Investment Management			M&A - Break Up / Divesiture	
Jnited States	3/21/2025	Teradata Corporation	Technology	\$2,166	Lynrock Lake	9.9%	\$214	Board Change, M&A - Agitate for Sale, Strategy / Operation	
Jnited States	3/20/2025	Elme Communities	Real Estate	\$1,504	Argosy Lionbridge Management	2.0%	\$30	Board Change	
Jnited States	3/20/2025	Cannae Holdings	Consumer	\$1,096	Carronade Capital Management	4.6%	\$50	Board Change, Capital Return, Strategy / Operations	
Jnited States	3/17/2025	National Vision Holdings	Retail	\$950	Engine Capital	3.2%	\$30	Board Change	
Jnited States	3/17/2025	Yeti Holdings	Industrials	\$2,801	Engaged Capital	1.9%	\$53	Board Change	
Jnited States	3/12/2025	Chemours Co.	Industrials	\$2,086	Vision One Management Partners	1.0%	\$21	Board Change	
Inited States	3/10/2025	Six Flags Entertainment	Communications & Media	\$3,615	Dendur Capital	2.8%	\$101	Board Change	
Inited States	3/10/2025	BlackLine Inc.	Technology	\$3,043	Scalar Gauge Fund	0.5%	\$15	Board Change	
Inited States	3/7/2025	Replimune Group	Healthcare	\$886	Baker Brothers Advisors	14.3%	\$127	Board Change	
Jnited States	3/7/2025	Cognizant Technology Solutions Corp.	Technology	\$41,167	Mantle Ridge	2.4%	\$988	Strategy / Operations	
Inited States	3/6/2025	Wex Inc.	Technology	\$5,985	Impactive Capital	6.7%	\$401	Strategy / Operations, Board Change, Governance	
Inited States	3/5/2025	Brookdale Senior Living Inc.	Healthcare	\$1,201	Ortelius Atlernative Investment Management	1.3%	\$16	Board Change	
Inited States	2/28/2025	Kite Realty	Real Estate	\$5,037	Land & Buildings	0.6%	\$30	M&A - Break Up / Divestiture / Capital Return	
Inited States	2/27/2025	Signet Jewelers Limited	Retail	\$2,163	Select Equity Group	9.7%	\$210	M&A - Agitate for Sale	
Jnited States	2/26/2025	Ingevity Corp.	Industrials	\$1,776	Vision One Management Partners	0.9%	\$16	Board Change, M&A - Break Up / Divestiture, Governance	
Jnited States	2/26/2025	Calumet Inc.	Industrials	\$1,328	Wasserstein Debt Opportunities Management	7.0%	\$93	Board Change, Governance	
Inited States	2/21/2025	Veradigm	Healthcare	\$865	Kent Lake Capital	4.8%	\$42	Board Change	
Inited States	2/18/2025	STAAR Surgical	Healthcare	\$819	Seven Corners Capital Management			Strategy / Operations, Capital Return	
Jnited States	2/13/2025	Beacon Roofing	Industrials	\$7,378	QXO, Inc.			Board Change, M&A - Agitate for Sale	
Jnited States	2/12/2025	Liberty Media	Communications & Media	\$32,044	ValueAct	5.5%	\$1,762	Board Change	
Jnited States	2/7/2025	AspenTech	Technology	\$17,397	Elliott Management	9.0%	\$1,566	M&A - Scuttle / Sweeten Deal	
Inited States	2/6/2025	LKQ Corporation	Industrials	\$9,715	Ancora Advisors / Engine Capital	2.6%	\$253	Board Change	
Inited States	2/4/2025	Evolent Health	Healthcare	\$1,195	Engaged Capital	3.4%	\$41	Board Change	
Inited States	2/3/2025	Becton Dickinson	Healthcare	\$71,098	Starboard Value			M&A - Break Up / Divestiture	
Jnited States	1/31/2025	Evolv Technologies	Technology	\$632	Stoic Point Capital	5.2%	\$33	Strategy / Operations	

Source: FactSet, 13D Monitor, Diligent Market Intelligence, Bloomberg, press reports and publicly available data and sources. Market data as of 3/31/2025.

Note: All data is for campaigns conducted globally by activists at companies with market capitalizations greater than \$500 million at time of campaign announcement; select campaigns with market capitalizations less than \$500 million due to depressed valuation at the time of campaign announcement (company was larger than \$500mm in prior twelve months).



Q1 2025 North America Campaigns

Country	Announce Date	Target	Sector	Market Cap	Activist	O/S%	Market Value	Initial Campaign Objective
United States	1/29/2025	Henry Schein	Healthcare	\$9,958	KKR	12.0%	\$1,195	Board Change
United States	1/28/2025	Riot Platforms	Technology	\$3,766	D.E. Shaw			No Public Activism
United States	1/27/2025	Vail Resorts	Real Estate	\$6,589	Late Apex Partners	3.5%	\$231	Management Change, Board Change, Capital Return, Strategy / Operations
United States	1/27/2025	U. S. Steel	Industrials	\$8,291	Ancora Advisors	0.2%	\$17	Board Change, M&A - Scuttle / Sweeten Deal, Management Change
United States	1/24/2025	UniFirst	Consumer	\$3,306	Voss Capital			M&A - Agitate for Sale
United States	1/24/2025	Middleby	Industrials	\$9,130	Garden Investments	5.0%	\$456	Board Change, M&A - Break Up / Divestiture, Strategy / Operations
United States	1/23/2025	Enviri	Industrials	\$739	Neuberger Berman	5.9%	\$44	Board Change
United States	1/17/2025	Qorvo	Technology	\$7,960	Starboard Value	7.7%	\$613	No Public Activism
United States	1/14/2025	Apartment Investment & Management	Real Estate	\$1,256	Land & Buildings	1.2%	\$15	M&A - Agitate for Sale
United States	1/7/2025	Orthofix Medical	Healthcare	\$652	Juniper Inv. Co	5.1%	\$33	No Public Activism



Q1 2025 Europe Campaigns


	Country	Announce Date	Target	Sector	Market Cap	Activist	O/S% I	Market Value	Initial Campaign Objective
L	Belgium	2/17/2025	Galapagos	Healthcare	\$1,707	Tang Capital Management	7.5%	\$128	Strategy / Operations, Governance
	Ireland	2/10/2025	Avadel	Healthcare	\$876	ASL Strategic Value Fund			Management Change, M&A - Agitate for Sale
	Italy	3/28/2025	Assicurazioni Generali SpA	Financial Institutions	\$55,425	Caltagirone Group	6.9%	\$3,824	Board Change
	Luxembourg	2/27/2025	SES	Communications & Media	\$1,727	Appaloosa	7.0%	\$121	Governance, Management Change, Board Change, Capital Return
	Spain	1/24/2025	Telefonica SA	Communications & Media	\$22,549	Green Bridge Investment	9.9%	\$2,232	Board Change
	United Kingdom	3/26/2025	Urban Logistics REIT	Real Estate	\$794	Waverton Investment Management / TR Property Investment Trust / Harwood Capital	8.8%	\$70	Board Change
	United Kingdom	2/10/2025	BP	Natural Resources	\$92,302	Elliott Management			Strategy / Operations
	United Kingdom	2/3/2025	Smiths Group	Industrials	\$8,649	Elliott Management	4.3%	\$372	Capital Return, M&A - Break Up / Divestiture
	United Kingdom	1/29/2025	Soho House	Consumer	\$436	Third Point	9.9%	\$43	M&A - Scuttle / Sweeten Deal
	United Kingdom	1/17/2025	Smiths Group	Industrials	\$7,787	Engine Capital	2.0%	\$156	M&A - Break Up / Divestiture



Q1 2025 APAC Campaigns

	Country	Announce Date	Target	Sector	Market Cap	Activist	O/S% I	Market Value	Initial Campaign Objective
米	Australia	3/17/2025	Austal	Industrials	\$1,015	Hanwha Aerospace	10%	\$101	Board Change, Strategy / Operations
	Japan	3/24/2025	Sumitomo Realty	Real Estate	\$19,082	Elliott Management			Strategy / Operations
	Japan	3/24/2025	Proto Corp,	Technology	\$585	Kaname Capital	8%	\$49	Board Change, M&A - Scuttle / Sweeten Deal
	Japan	3/19/2025	Stanley Electric	Industrials	\$2,722	Murakami Funds	5%	\$139	No Public Activism
	Japan	3/14/2025	Ferrotec Holdings Corp.	Technology	\$909	Murakami Funds	5%	\$48	No Public Activism
	Japan	3/10/2025	Macnica Holdings	Retail	\$2,336	Dalton Investments	5%	\$117	Strategy / Operations, Board Change
	Japan	3/3/2025	DIC Corp.	Industrials	\$2,042	Oasis Management	12%	\$235	Board Change
	Japan	2/20/2025	Keikyu Corporation	Industrials	\$2,822	Murakami Funds	5%	\$144	No Public Activism
	Japan	2/17/2025	Taiyo Holdings	Technology	\$1,500	Oasis Management	8%	\$120	No Public Activism
	Japan	2/13/2025	Mitsubishi Pencil	Consumer	\$900	Nippon Active Value Fund			Capital Return, Governance
	Japan	2/12/2025	Astellas Pharma	Healthcare	\$16,972	Farallon Capital	3%	\$509	Strategy / Operations
	Japan	1/28/2025	Fuji Media Holdings	Communications & Media	\$3,060	Zennor Asset Management	1%	\$31	Board Change
	Japan	1/24/2025	Topcon Corp	Technology	\$2,004	Oasis Management	7%	\$148	No Public Activism
	Japan	1/24/2025	Nikkon	Industrials	\$1,772	Farallon Capital Mgmt.	5%	\$90	No Public Activism
	Japan	1/22/2025	Oji HDS	Industrials	\$3,950	Murakami Funds	5%	\$201	No Public Activism
	Japan	1/20/2025	Noritz Corp.	Industrials	\$546	Nippon Active Value Fund	3%	\$17	Governance, Capital Return
	Japan	1/20/2025	Furukawa	Technology	\$3,232	Murakami Funds	5%	\$165	No Public Activism
	South Korea	1/21/2025	Coway	Consumer	\$4,126	Align Partners	3%	\$116	Board Change, Strategy / Operations, Capital Return





Q1 2025 Board Seats Won

•				
Date Appointed	Company	Board Seats	Names	Activist
1/13/2025	Graftech International	2	Sachin Shivaram, Eric Roegner	Nilesh Undavia
1/23/2025	Air Products and Chemicals	3	Paul Hilal*, Dennis Reilly, Andrew Evans	Mantle Ridge
1/23/2025	Enviri	2	TBU	Neuberger Berman
1/29/2025	Henry Schein	2	Dan Daniel*, Max Lin*	KKR
2/4/2025	Evolent Health	1	Bruce Springstubb*	Engaged Capital
2/4/2025	Dave & Buster's Entertainment Inc.	1	Scott Ross*	Hill Path Capital
2/6/2025	LKQ Corporation	2	Sue Gove, Michael Powell	Ancora Advisors / Engine Capital
2/10/2025	nCino	1	Justin Nyweide*	HMI Capital Mgmt.
2/13/2025	Riot Platforms	3	Jamie Leverton, Doug Mouton, Michael Turner	Starboard Value / D.E. Shaw
2/14/2025	CAE Inc	1	Peter Lee*	Browning West
2/21/2025	Veradigm	4	Vinit Asar, Louis Silverman, Bruce Felt, Jonathan Sacks*	Kent Lake Capital
2/21/2025	Fortrea Holdings	2	Erin Russell, TBU*	Starboard Value
2/25/2025	Middleby	1	Ed Garden*	Garden Investments
3/3/2025	Telefonica SA	1	Olawayan Alwetaid*	Green Bridge Investment
3/3/2025	Daktronics	1	Peter Geigin	Alta Fox
3/5/2025	Kenvue	3	Sarah Hofstetter, Erica Mann, Jeff Smith*	Starboard Value
3/7/2025	Replimune Group	1	Micahel Goller*	Baker Brothers Advisors
3/10/2025	BlackLine Inc.	1	Scott Davidson	Scalar Gauge Fund
3/10/2025	Six Flags Entertainment	2	Felipe Dutra, Steven Hoffman	Dendur Capital
3/12/2025	Chemours Co.	1	Courtney Mather*	Vision One Management Partners
3/14/2025	Algonquin Power & Utilities Corp	1	Gavin Molinelli*	Starboard Value
3/17/2025	Yeti Holdings	2	Jan Welander, Arne Arens	Engaged Capital
3/17/2025	National Vision Holdings	2	Jim McGrann, Mike Nicholson	Engine Capital
3/18/2025	Caesars Entertainment	2	Ted Papapostolou*, Jesse Lynn*	Icahn Associates
3/18/2025	Calumet Inc.	2	Karen Narwold, Julio Quintana	Wasserstein Debt Opportunities Fund
3/20/2025	Elme Communities	1	Ron Sturzzenegger	Argosy Lionbridge Management
3/24/2025	Rapid7	3	Wael Mohamed, Mike Burns, Kevin Galligan*	JANA Partners
3/25/2025	Illumina	1	Keith Meister*	Corvex Mgmt.
3/31/2025	Warner Bros Discovery	1	Anton Levy	Sessa Capital
3/31/2025	Ingevity	1	David Segal	Vision One Management Partners



Disclaimer

This document has been prepared by Barclays Capital Inc. ("Barclays") for information purposes only. This document is an indicative summary of the terms and conditions of certain corporate transactions described herein and may be amended, superseded or replaced by subsequent summaries. Moreover, any information provided herein was not prepared for or intended for use by any individual for personal, family or household purposes.

This document was prepared on the basis of information and data, obtained from publicly available sources, in each case prior to or on the date hereof. Barclays makes no warranty or representation, express or implied, as to the accuracy or completeness of information which is contained in this document and which is stated to have been obtained from or is based upon trade and statistical services or other third party sources. The information in this document has not been independently verified by Barclays and Barclays does not assume any liability for any such information. Any data on past performance, modelling, scenario analysis or back-testing contained herein is no indication as to future performance. No warranty or representation is made as to the reasonableness of any assumptions made within or the accuracy or completeness of any modelling, scenario analysis or back-testing or any other information contained herein. All opinions and estimates are given as of the date hereof and are subject to change and Barclays assumes no obligation to update this document to reflect any such changes. The value of any investment may fluctuate as a result of market changes. The information herein is not intended to predict actual results and no assurances are given with respect thereto. Nothing herein shall be deemed to constitute a recommendation or investment, legal, tax, financial, accounting or other advice.

The recipient is responsible for making its own independent investigation and appraisal of the risks, benefits, appropriateness and suitability of any corporate transaction or commercial or business matter contemplated by this document and Barclays is not making any recommendation (personal, family, household or otherwise) or giving any investment advice and will have no liability with respect thereto. The decision to proceed with any corporate transaction or commercial or business action contemplated by this document must be made by the recipient in the light of its own commercial assessments and Barclays will not be responsible for such assessments.

Neither Barclays nor any of its subsidiaries or affiliates, nor any of their respective directors, officers, employees, advisors or other representatives (Barclays together with such persons being the "Barclays Group") accepts any liability whatsoever for any direct, indirect or consequential losses (in contract, tort or otherwise) arising from the use of this document or its contents or any reliance on the information contained herein. Barclays Group is not responsible for any specialized advice (including financial, tax, legal, regulatory and accounting, or other advice).

This document does not constitute nor does it form part of an offer to sell or purchase, or the solicitation of an offer to sell or purchase, any securities or any of the businesses or assets described herein or an offer or recommendation to enter into any corporate transaction described herein nor does this document constitute an offer or commitment to provide, arrange or underwrite any financing.

Members of the Barclays Group are involved in a wide range of commercial banking, investment banking and other activities out of which conflicting interests or duties may arise. In the ordinary course of its business, the Barclays Group may provide services to any entity or person referred to herein, engage in any corporate transaction (whether on its own account, on behalf of any third party or otherwise, and including any corporate transaction or commercial or business matter contemplated by this document), notwithstanding that such services, transactions or actions may be adverse to any recipient of this document, and the Barclays Group may retain for its own benefit any related remuneration or profit. The Barclays Group operates in accordance with a conflicts of interest policy which identifies conflicts or interest it faces in the ordinary course of its business, and establishes organizational and procedural measures to manage those conflicts where it is reasonably able to do so. Neither Barclays Group shall have any duty to disclose to any recipient of this document any non-public information acquired in the course of providing services to any other person, engaging in any transaction (on its own account or otherwise) or otherwise carrying on its business. Barclays is a full service securities firm and as such from time may effect transactions for its own account or the account of its clients and hold long or short positions in debt, equity or other securities of the companies referred to herein or in other financial products and instruments. Unless otherwise expressly agreed or provided for in other applicable Barclays disclosures governing such transactions or required by law or regulation, Barclays conducts these activities as principal and executes its principal transactions as an arm's length counterparty. Barclays does not act as a fiduciary in relation to these corporate transactions.

This material has not been produced by the Barclays Group's research department and does not constitute investment research or a research recommendation for the purposes of Financial Conduct Authority rules or a research report under U.S. law. The Barclays Group's research analysts and research departments are independent from Barclays' banking business and are subject to certain regulations and internal policies. The Barclays Group's research analysts may hold and make statements or investment recommendations and/or publish research reports with respect to any company referred to herein, the corporate transactions contemplated herein or any person involved therein or related thereto that differ from or are inconsistent with the views or advice communicated by the Barclays Group's banking business.

NO ACTION HAS BEEN MADE OR WILL BE TAKEN THAT WOULD PERMIT A PUBLIC OFFERING OF ANY SECURITIES, FINANCIAL INSTRUMENT OR OTHER CORPORATE TRANSACTION DESCRIBED HEREIN IN ANY JURISDICTION IN WHICH ACTION FOR THAT PURPOSE IS REQUIRED. NO OFFERS, SALES, RESALES OR DELIVERY OF ANY SECURITIES OR INSTRUMENTS DESCRIBED HEREIN OR DISTRIBUTION OF ANY OFFERING MATERIAL RELATING TO ANY SUCH SECURITIES, FINANCIAL INSTRUMENTS OR CORPORATE TRANSACTIONS MAY BE MADE IN OR FROM ANY JURISDICTION EXCEPT IN CIRCUMSTANCES WHICH WILL RESULT IN COMPLIANCE WITH ANY APPLICABLE LAWS AND REGULATIONS AND WHICH WILL NOT IMPOSE ANY OBLIGATION ON BARCLAYS OR ANY OF ITS AFFILIATES.

THIS DOCUMENT DOES NOT DISCLOSE ALL THE RISKS AND OTHER SIGNIFICANT ISSUES RELATED TO AN INVESTMENT IN THE SECURITIES, FINANCIAL INSTRUMENTS OR CORPORATE TRANSACTIONS DESCRIBED HEREIN.

THE INFORMATION CONTAINED HEREIN IS NOT INTENDED TO BE DISTRIBUTED TO ANY PROSPECTIVE OR ACTUAL INVESTORS AND, ACCORDINGLY, MAY NOT BE SHOWN OR GIVEN TO ANY PERSON OTHER THAN THE RECIPIENT, AND IS NOT TO BE FORWARDED TO ANY OTHER PERSON (INCLUDING ANY RETAIL INVESTOR OR CUSTOMER), COPIED OR OTHERWISE REPRODUCED OR DISTRIBUTED TO ANY SUCH PERSON IN ANY MANNER WHATSOEVER, FAILURE TO COMPLY WITH THIS DIRECTIVE CAN RESULT IN A VIOLATION OF THE SECURITIES ACT OF 1933, AS AMENDED.

Barclays Capital Inc. is the United States investment bank of Barclays Bank PLC. Barclays Bank PLC is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority (Financial Services Register No. 122702). Registered in England. Registered No. 1026167. Registered office: 1 Churchill Place, London E14 5HP. Copyright Barclays Bank PLC, Q1 2025 (all rights reserved).

